bs-3483R-Biotin [Conjugated Primary Antibody]
CDK2 (Thr160) Polyclonal Antibody, Biotin Conjugated
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: CDK2 Thr160

Modification Site: Thr160

Clonality: Polyclonal

Isotype: IgG

Entrez Gene: 1017

Source: KLH conjugated synthetic phosphopeptide derived from human CDK2 around the phosphorylation site of Thr160 [TY(p-T)HE]

Purification: Purified by Protein A.

Storage Buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Store at -20°C for 12 months.

Background:

The protein encoded by this gene is a member of the Ser/Thr protein kinase family. This protein kinase is highly similar to the gene products of S. cerevisiae cdc28, and S. pombe cdc2. It is a catalytic subunit of the cyclin-dependent protein kinase complex, whose activity is restricted to the G1-S phase, and essential for cell cycle G1/S phase transition. This protein associates with and regulated by the regulatory subunits of the complex including cyclin A or E, CDK inhibitor p21Cip1 (CDKN1A) and p27Kip1 (CDKN1B). Its activity is also regulated by its protein phosphorylation. Two alternatively spliced variants and multiple transcription initiation sites of this gene have been reported. [provided by RefSeq, Jul 2008].

Conjugation: Biotin

Excitation/ Emission: N/A

Size: 100ul

Concentration: 1ug/ul

Applications: WB(1:300-5000)
IHC-P(1:200-400)

Cross Reactive Species: Human
Mouse
Rat

For research use only. Not intended for diagnostic or therapeutic use.

PRODUCT SPECIFIC PUBLICATIONS
  • Mlcochova, Petra, et al. "A G1‐like state allows HIV‐1 to bypass SAMHD1 restriction in macrophages." The EMBO Journal (2017): e201696025.Read more>>
  • Kaikai Gong. et al. Aaptamine attenuates the proliferation and progression of non-small cell lung carcinoma. Pharm Biol. 2020;58(1):1044-1054Read more>>
  • ang-Hua Zhong. et al. Transcription factor FOXF2 promotes the development and progression of pancreatic cancer by targeting MSI2. ONCOL REP. 2024 Jul;52(1):1-13Read more>>
VALIDATION IMAGES